Tetrous, a start-up focused on bone-to-tendon healing following orthopedic surgery, has earned a fourth patent related to its EnFix family of demineralized cortical bone fiber implants.
The EnFix family of products is designed to enhance healing at the tendon-to-bone interface, according to an Oct. 15 press release.
The implants provide osteoinductivity and osteoconductivity, while Tetrous' "FormLok" technology gives the device shape retention, even in the wet environment of arthroscopic surgery.
The newly issued patent is titled "Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair."
More than 700 EnFix RC and EnFix TAC implants have been implanted in the U.S. and Australia since July 1, 2023, according to the release.